AccurayShares of Accuray ( ARAY) tumbled in Monday's extended session, losing 8% to $4.51 on volume of around 15,000, after the Sunnyvale, Calif.-based radiation oncology company posted a surprise loss in its fiscal fourth quarter and gave a weak first-quarter outlook. Including charges and expenses totaling $18.7 million related to its TomoTherapy acquisition, the company said it lost $25 million, or 40 cents a share, in the three months ended June 30 with revenue totaling $75.2 million. The average estimate of analysts polled by Thomson Reuters was for earnings of 7 cents a share in the June-ended period on revenue of $64.8 million. For its fiscal first quarter ending in September, Accuray said it sees revenue of $80 million to $85 million, below Wall Street's current consensus view of $93.3 million. For fiscal 2012, the company forecast revenue of between $400 million and $415 million, which is ahead of the average analysts' estimate of $377.7 million.